WGS250117P110000
- 0.00
- 0.000.00%
GeneDx Holdings Newsroom
Genedx Holdings Insider Sold Shares Worth $3,331,024, According to a Recent SEC Filing
GeneDx Holdings(WGS.US) Officer Sells US$3.33 Million in Common Stock
$GeneDx Holdings(WGS.US)$ Officer Feeley Kevin sold 35,506 shares of common stock on Jan 7, 2025 at an average price of $93.8158 for a total value of $3.33 million.Source: Announcement What is
GeneDx Holdings(WGS.US) Officer Sells US$4.86 Million in Common Stock
$GeneDx Holdings(WGS.US)$ Officer Stueland Katherine sold 51,420 shares of common stock on Jan 7, 2025 at an average price of $94.4792 for a total value of $4.86 million.Source: Announcement What is
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating
GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers
GeneDx Continues Its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
GeneDx Shares Are Trading Higher After TD Cowen Raised Its Price Target From $75 to $118.
GeneDx Hldgs Analyst Ratings
TD Cowen Maintains GeneDx Holdings(WGS.US) With Buy Rating, Raises Target Price to $118
TD Cowen Reaffirms Their Buy Rating on GeneDx Holdings (WGS)
GeneDx Holdings (WGS) Surges 13.2%: Is This an Indication of Further Gains?
GeneDx Holdings (NASDAQ:WGS) Has Debt But No Earnings; Should You Worry?
Resources Connection, SPS Commerce And 3 Stocks To Watch Heading Into Friday
GeneDx Names Dechairo as First Chief Operating Officer
GeneDx Strengthens Executive Leadership Team With Bryan Dechairo Named Chief Operating Officer >WGS
GeneDx Strengthens Executive Leadership Team With Bryan Dechairo Named Chief Operating Officer
Top-rated Smaller Defensive Stocks After Societe Generale Permabear Takes Contrarian View
Institutional Investors Control 59% of GeneDx Holdings Corp. (NASDAQ:WGS) and Were Rewarded Last Week After Stock Increased 3.5%
GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GeneDx Announces Biogen, Praxis Precision Medicines And Stoke Therapeutics As The Founding Partners To Its Patient Access Program For Pediatric Epilepsy, Which Provides Access To Whole Exome Sequencing.